Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Payables (2020 - 2025)

Historic Payables for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $38.6 million.

  • Apellis Pharmaceuticals' Payables fell 966.07% to $38.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.6 million, marking a year-over-year decrease of 966.07%. This contributed to the annual value of $38.6 million for FY2024, which is 281.48% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Payables stood at $38.6 million for Q3 2025, which was down 966.07% from $54.2 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Payables registered a high of $55.3 million during Q1 2025, and its lowest value of $4.2 million during Q1 2021.
  • Its 5-year average for Payables is $27.4 million, with a median of $27.5 million in 2023.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Payables plummeted by 5497.33% in 2021, and later skyrocketed by 20380.22% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Payables (Quarter) stood at $16.9 million in 2021, then soared by 120.84% to $37.3 million in 2022, then increased by 0.47% to $37.5 million in 2023, then grew by 2.81% to $38.6 million in 2024, then grew by 0.08% to $38.6 million in 2025.
  • Its Payables stands at $38.6 million for Q3 2025, versus $54.2 million for Q2 2025 and $55.3 million for Q1 2025.